Anticipation is running high for Biogen Idec’s new multiple sclerosis (MS) drug, Antegren. The drug was given accelerated approval status, with the FDA expected to release its judgment around Thanksgiving of this year. A monoclonal antibody, the drug performed well in Phase II studies.
